Amino Acid, Peptide, or Protein
Novo Nordisk’s Wegovy Pill Launches Strongly Amid Analyst Caution
Wegovy pill; Novo Nordisk; FDA approval; oral GLP-1; obesity drug; Eli Lilly competition
Sanofi’s Amlitelimab Shows Mixed Phase 3 Results in Eczema Trials, Clouds Blockbuster Hopes but Advances to Regulatory Filings
Sanofi; amlitelimab; Phase 3; eczema; atopic dermatitis; COAST; SHORE; vIGA-AD; EASI-75
Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11
Corxel Pharmaceuticals; Series D1; GLP-1; CX11; obesity drug; funding; Vincentage
BioMarin Veterans Launch Mendra Biotech with $82M for AI-Driven Rare Disease Drugs
Mendra; BioMarin; rare disease; biotech startup; $82M; Series A; AI drug development
J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff
Johnson & Johnson; J&J; 2026 sales; $100 billion; Stelara; patent cliff; DARZALEX; oncology; MedTech; Shockwave Medical
Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward
childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule
Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b
AstraZeneca Acquires Complete Global Rights to AbelZeta’s C-CAR031 CAR-T Therapy for Up to $630 Million
AstraZeneca; AbelZeta; C-CAR031; CAR-T; GPC3; China rights; $630M; hepatocellular carcinoma; HCC
Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial
Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival